Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -59.88% is 43% above its 5-year average of -105.87%, near the high end of its 5-year range (-153.92%–-36.38%).
48.79% above its 12-month average of -116.93%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -39.26%.
RETURN ON ASSETS (ROA)
-59.88%
RETURN ON ASSETS (ROA) AVG TTM
-116.93%
RETURN ON ASSETS (ROA) AVG 3Y
-132.27%
RETURN ON ASSETS (ROA) AVG 5Y
-105.87%
RETURN ON ASSETS (ROA) AVG 10Y
-89.87%
RETURN ON ASSETS (ROA) AVG 15Y
-72.11%
RETURN ON ASSETS (ROA) AVG 20Y
-56.00%
CURRENT VS TTM AVG
+48.79%
CURRENT VS 3Y AVG
+54.73%
CURRENT VS 5Y AVG
+43.44%
CURRENT VS 10Y AVG
+33.37%
CURRENT VS 15Y AVG
+16.96%
CURRENT VS 20Y AVG
-6.93%
SECTOR MEDIAN · HEALTHCARE
-26.45%
median of 501 covered companies
CURRENT VS SECTOR MEDIAN
-126.39%
vs the sector median at left
Achieve Life Sciences, Inc.
Market Cap
$724.77M
Return on Assets (ROA)
-59.88%
TTM Avg
-116.93%
3Y Avg
-132.27%
5Y Avg
-105.87%
Market Cap
$709.33M
Return on Assets (ROA)
2.24%
TTM Avg
3.98%
3Y Avg
2.51%
5Y Avg
4.09%
Market Cap
$707.86M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$737.02M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$698.60M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
Market Cap
$756.15M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$689.78M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$675.41M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$766.41M
Return on Assets (ROA)
-20.44%
TTM Avg
-45.26%
3Y Avg
-91.41%
5Y Avg
-102.66%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Achieve Life Sciences, Inc. (ACHV) | $724.77M | -59.88% | -116.93% | -132.27% | -105.87% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.24% | 3.98% | 2.51% | 4.09% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | -70.67% | -51.05% | -54.02% | -55.25% |
| Anteris Technologies Global Corp. (AVR)vs › | $737.02M | -38.01% | -251.96% | -211.47% | -174.45% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -103.29% | -79.28% | -61.36% | -60.54% |
| Candel Therapeutics, Inc. (CADL)vs › | $756.15M | -42.53% | -41.06% | -49.54% | -47.47% |
| Annexon, Inc. (ANNX)vs › | $689.78M | -82.36% | -56.97% | -52.21% | -45.34% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -36.37% | -26.71% | -31.04% | -27.33% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $766.41M | -20.44% | -45.26% | -91.41% | -102.66% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.54M | -36.55% | -44.22% | -44.22% | -44.22% |
ROA
-59.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -130.77% |
| 2024-12-31 | -103.09% |
| 2023-12-31 | -153.92% |
| 2022-12-31 | -141.30% |
| 2021-12-31 | -69.77% |
| 2020-12-31 | -36.38% |
| 2019-12-31 | -77.78% |
| 2018-12-31 | -66.48% |
| 2017-12-31 | -106.99% |
| 2016-12-31 | -73.28% |
| 2015-12-31 | -28.86% |
| 2014-12-31 | -46.61% |
| 2013-12-31 | -57.19% |
| 2012-12-31 | -25.72% |
| 2011-12-31 | -21.57% |
| 2010-12-31 | -13.99% |
| 2009-12-31 | 7.94% |
| 2008-12-31 | -28.42% |
| 2007-12-31 | -28.87% |
| 2006-12-31 | -34.38% |
| 2005-12-31 | -36.43% |
| 2004-12-31 | -72.26% |
| 2003-12-31 | -48.76% |
| 2002-12-31 | -64.88% |
| 2001-12-31 | 3.42% |
| 2000-12-31 | -15.01% |
| 1999-12-31 | 2.21% |
| 1998-12-31 | -59.57% |
| 1997-12-31 | 3.46% |
| 1996-12-31 | 6.34% |
